Vir Biotechnology (NASDAQ:VIR) Rating Reiterated by HC Wainwright

Vir Biotechnology (NASDAQ:VIR)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $110.00 price objective on the stock.

A number of other research analysts also recently weighed in on VIR. Needham & Company LLC increased their price target on Vir Biotechnology from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, June 5th. Barclays increased their target price on Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. boosted their target price on Vir Biotechnology from $10.00 to $12.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, Morgan Stanley increased their price target on shares of Vir Biotechnology from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Thursday, June 6th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Vir Biotechnology Stock Down 1.6 %

Shares of VIR opened at $8.67 on Tuesday. The company has a 50-day moving average price of $9.24 and a two-hundred day moving average price of $9.72. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -2.16 and a beta of 0.48. Vir Biotechnology has a 12 month low of $7.61 and a 12 month high of $13.27.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Thursday, August 1st. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.13). The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $7.53 million. Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. Vir Biotechnology’s quarterly revenue was down 19.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.45) earnings per share. Equities research analysts expect that Vir Biotechnology will post -3.26 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Saira Ramasastry sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $10.95, for a total transaction of $43,800.00. Following the completion of the transaction, the director now directly owns 14,619 shares in the company, valued at $160,078.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.60% of the stock is owned by corporate insiders.

Institutional Trading of Vir Biotechnology

Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in Vir Biotechnology by 249.9% in the 1st quarter. GAMMA Investing LLC now owns 2,708 shares of the company’s stock valued at $27,000 after purchasing an additional 1,934 shares during the period. Quadrant Capital Group LLC boosted its holdings in shares of Vir Biotechnology by 274.5% in the 4th quarter. Quadrant Capital Group LLC now owns 2,970 shares of the company’s stock worth $30,000 after buying an additional 2,177 shares during the last quarter. Innealta Capital LLC purchased a new position in shares of Vir Biotechnology in the 2nd quarter worth about $32,000. Signaturefd LLC grew its position in Vir Biotechnology by 258.5% during the fourth quarter. Signaturefd LLC now owns 3,327 shares of the company’s stock valued at $33,000 after buying an additional 2,399 shares during the period. Finally, Federated Hermes Inc. purchased a new stake in Vir Biotechnology during the fourth quarter worth about $69,000. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.